EICHOR
● Recruiting
A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors
Condition: Advanced Malignant Tumors · Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
About this study
This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and anti-tumor activity of SSGJ-709 as a single agent in patients with advanced malignancies.
This description comes directly from the study's public registry record.
Talk to the study team
Andrew Parsonson · +61 2 9812 3538 · andrew.parsonson@mqhealth.org.au
Always discuss trial participation with your own doctor first.
Locations (1)
| Southern Oncology Clinical Research Unit (SOCRU) | Adelaide, Australia | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07016490